Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly
Govt okays Rs 4,500 cr upfront payment for 300 mn doses
With the launch, the company has become the first Indian and second global firm to develop the drug, which is a generic version of Abbott's Duphaston
Access to the private market, international sales are other factors that will impact margins
Zydus had recently also slashed prices of its remdesivir brand Remdac to Rs 899 per dose
Pharma major Dr Reddy's Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said
The mansion is one of the largest residences in the neighborhood and measures about 25,000 square feet (2,322 square meters), the equivalent of about 24 average English homes
Bharat Biotech also has another site at Bengaluru that is currently making vaccines other than Covaxin
Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January
AstraZeneca Chief Executive (CEO) Pascal Soriot has indicated that the company may look at factories outside of the EU to meet the supply commitments.
Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets
16 schemes from equal numbers of companies have been approved to boost local production, value addition and, consequently, export of mobile phones.
The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials
Bharat Bio says keen to follow, have capacity of 40 mn doses a month
Aims to launch the vaccine in March if regulator approval comes through
Data shows that cumulative sales of remdesivir was Rs 510 crore in January 2021, while for favipiravir it was Rs 471 crore
According to the people, 86 companies have applied to start production of bulk drugs listed under the PLI scheme so far, said sources
Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established
Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"
The foreign ministry said shipments would start on Wednesday following requests from "neighbouring and key partner countries"